Livia Cristina Dias

The study evaluated bone repair in tibial defects of Wistar rats treated with 45S5 bioactive glass, either alone or combined with lyophilized heterologous fibrin biopolymer (HFB) and/or photobiomodulation therapy (PBM). Thirty-five animals were randomly assigned to five groups: control (CG), Bioactive glass (BG), Bioactive glass + HFB (BFG), Bioactive glass + PBM (BPG), and Bioactive glass + HFB + PBM (BFPG). After 42 days, the samples were analyzed by micro-computed tomography, histology (Hematoxylin–Eosin, Masson’s Trichrome, and Picrosirius Red), and histomorphometry. Histological and micro-CT findings demonstrated improved defect closure and better matrix organization in the BG and BFG groups. Histomorphometric analysis revealed significant differences among the groups (ANOVA, p < 0.0001), with the BG group showing the highest percentage of new bone formation (40.35 ± 4.14%), significantly higher than the BPG and BFPG groups. The addition of HFB did not impair bone repair and yielded intermediate results, whereas PBM did not demonstrate a positive effect on bone regeneration at the 42-day time point under the parameters used in this study. It can be concluded that bioactive glass, especially when used alone or in combination with heterologous fibrin biopolymer, promoted superior bone regeneration, while its association with photobiomodulation did not demonstrate additional benefit at 42 days.

Cannabidiol (CBD) is a non-psychotropic compound found in plants of the Cannabis genus, extensively studied for its therapeutic potential. Research has shown that CBD possesses anti-inflammatory, antioxidant, and regenerative properties, and may contribute to the recovery of neural and bone tissues. In light of the aging population and the resulting rise in neurodegenerative and osteodegenerative conditions, exploring novel therapeutic strategies that promote cellular regeneration is increasingly important. This review aims to compile and critically analyze key studies published in recent decades regarding the effects of CBD on the regeneration of the central and peripheral nervous systems, as well as bone tissue. Findings from in vivo studies indicate that CBD can attenuate inflammatory responses, inhibit oxidative stress, and modulate cellular pathways involved in tissue repair, thereby supporting neuronal and bone regeneration. Moreover, evidence suggests that CBD may protect cells from structural damage, enhancing the functional recovery of affected tissues. Despite scientific advances highlighting cannabidiol as a promising agent for bone and nerve regeneration, its therapeutic application still faces significant limitations. The primary challenge lies in the lack of robust clinical trials in humans, as most existing evidence is derived from in vitro and in vivo studies, making it difficult to confirm its efficacy and safety in clinical contexts. Additionally, CBD’s low bioavailability—due to first-pass hepatic metabolism—hinders dose standardization and reduces the predictability of therapeutic outcomes. Compounding these issues are regulatory constraints and the persistent social stigma surrounding cannabis-derived compounds, which further impede their integration and acceptance in regenerative medicine. Therefore, future research is essential to validate the therapeutic benefits of CBD and to establish its clinical applicability in treating neurological and bone disorders.